1. Scrip
  2. >>R&D

Erasca Unveils First Clinical Candidates, Aims To Create A MAPK Clamp

SHP2, ERK Inhibitors Disclosed After Two Years, $300m In Funding

 
• By Mandy Jackson

Former Ignyta CEO’s well-funded Erasca obtained its first clinical-stage precision oncology candidates from NiKang and Asana, eyeing a first-in-class approach to RAS/MAPK-driven cancers.

staircase pathway in the beautiful forest
Erasca's first disclosed programs aim to shut down the RAS/MAPK pathway • Source: Shutterstock

Erasca Inc. launched at the end of 2018 with $42m, a high-profile CEO and undisclosed precision oncology programs with the ambitious goal of “erasing cancer.” Even after raising another $200m in April of last year, the company founded and helmed by Jonathan Lim – who was heading up Ignyta, Inc. when Roche Holding AG agreed to buy it in 2017 for $1.7bn – declined to describe its cancer drug development programs. But now that Erasca has initiated its first clinical trial, the company is ready to unveil its first two drug candidates.

The San Diego-based company has accomplished a lot during the two years since its series A venture capital round. Including...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Aurobindo Expects Lannett Acquisition To Pass FTC Scrutiny; Q1 US Revenue Falls

 
• By Vibha Ravi

Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline

Cardiff Pushes Towards Colorectal Cancer Phase III As Funding Questions Loom

 
• By Manas Mishra

Cardiff Oncology is open to going it alone, a partnership and even an exit as the San Diego, CA-based firm tries to push its PLK1 inhibitor through late-stage development.

Aurigene Oncology CEO On Biotech Valuations, CAR-Ts And Reimbursement Models

 
• By Anju Ghangurde

Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.